View EasOtic Otic Suspension Drug Facts Sheet.
Verify that the tympanic membrane is intact. Shake well before each use.
Priming the canister: Prior to the first use of the dosing canister, prime the pump by depressing the pump 1 to 2 times to fill the clear canula (tip) with a full dose of product.
Carefully insert the canula into the affected external ear canal(s) and apply 1 mL (a single pump) of Otic Suspension once per day for 5 days. Wash hands after usage.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Do not use in dogs with known tympanic membrane perforation.
EasOtic Otic Suspension is contraindicated in dogs with known or suspected hypersensitivity to corticosteroids, imidazole antifungals, or aminoglycoside antibiotics.
Human Warnings: Not for use in humans. Keep this and all drugs out of reach of children. In case of accidental skin contact, wash area thoroughly with water. Avoid contact with eyes.
Humans with known or suspected hypersensitivity to hydrocortisone, aminoglycoside antibiotics, or azole antifungals should not handle this product.
In case of accidental ingestion by humans, contact a physician immediately. Physicians may contact a Poison Control Center for advice concerning cases of ingestion by humans.
Animal Warnings: As a class, aminoglycoside antibiotics are associated with ototoxicty, vestibular dysfunction and renal toxicity. The use of EasOtic Otic Suspension in a dog with a damaged tympanic membrane can result in damage to the structures of the ear associated with hearing and balance or in transmission of the infection to the middle or inner ear. Immediately discontinue use of EasOtic Otic Suspension if hearing loss or signs of vestibular dysfunction are observed during treatment (see Adverse Reactions).
Do not administer orally. Concurrent administration of potentially ototoxic drugs should be avoided.Use with caution in dogs with impaired hepatic or renal function (see Animal Safety).
Long-term use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see Animal Safety).
The safe use of EasOtic Otic Suspension in dogs used for breeding purposes, during pregnancy, or in lactating bitches, has not been evaluated.
In a field study conducted in the United States (see Effectiveness), there were no adverse reactions reported in 145 dogs administered EasOtic Otic Supsension.
In foreign market experience, reports of hearing loss and application site erythema have been received. In most reported cases, the hearing loss and erythema were transient and resolved with discontinuation of EasOtic suspension.To report suspected adverse drug events, contact Virbac at 800-338-3659 or the FDA at 1-888-FDA-VETS.
For technical assistance or to obtain a Safety Data Sheet, call Virbac at 800-338-3659.
The effectiveness of this drug was evaluated in 157 dogs with otitis externa. The study was a double-masked field study with a placebo control. One hundred and four dogs were treated with EasOtic Otic Suspension and 53 dogs were treated with the placebo control. Treatment was administered once daily for 5 consecutive days to the affected ear(s). The dogs were evaluated at 4 different intervals over the course of 1 month to determine response to therapy. The 6 clinical signs evaluated were: malodor, aural discharge, pruritus, erythema, swelling and pain. The individual clinical scores were assigned based on the severity of each sign. Success was based on clinical improvement at Day 28 ±2 days. The success rates of the 2 groups were significantly different (p=0.0179); 68.5% of dogs administered EasOtic Otic Suspension were successfully treated, compared to 21.8% of the dogs in the placebo control group.
In the target animal safety study, EasOtic Otic Suspension was administered at 0X, 1X, 3X and 5X the recommended dose for 15 consecutive days (3 times the recommended treatment duration) in laboratory Beagles, with 8 dogs per group. Hypersensitivity reactions in the external ear canal and inner pinnae were seen in all EasOtic Otic Suspension groups and included mild to severe aural erythema (3X group), papules and ulceration (1X and 5X groups), otitis externa (3X and 5X groups), and otitis media (5X group). Renal tubular crystals were present in the cortex and medulla (0X, 1X, 3X, and 5X groups) and mild renal tubular basophilia and atrophy were present in one 5X group dog. Baseline cortisol values and the cortisol response to ACTH stimulation were lower in treated dogs compared to the control dogs. The ACTH stimulation test results are consistent with systemic absorption of topical corticosteroids causing suppression of the hypothalamic-pituitary-adrenal axis. Dogs in the 3X and 5X groups demonstrated elevations in AST and ALP, while dogs in the 1X, 3X, and 5X groups had elevated cholesterol, total protein, and albumin levels. Dogs in the 3X and 5X groups also had higher liver weights and greater food consumption.
Store at temperatures between 20°C-25°C (68°F-77°F), with excursions permitted between 15°C-30°C (59°F-86°F).